GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » BioPharma Credit PLC (LSE:BPCR) » Definitions » EV-to-FCF

BioPharma Credit (LSE:BPCR) EV-to-FCF : 5.13 (As of May. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is BioPharma Credit EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioPharma Credit's Enterprise Value is $945.2 Mil. BioPharma Credit's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 was $184.3 Mil. Therefore, BioPharma Credit's EV-to-FCF for today is 5.13.

The historical rank and industry rank for BioPharma Credit's EV-to-FCF or its related term are showing as below:

LSE:BPCR' s EV-to-FCF Range Over the Past 10 Years
Min: 5.13   Med: 9.61   Max: 20.33
Current: 5.13

During the past 7 years, the highest EV-to-FCF of BioPharma Credit was 20.33. The lowest was 5.13. And the median was 9.61.

LSE:BPCR's EV-to-FCF is ranked better than
81.96% of 1059 companies
in the Asset Management industry
Industry Median: 13.36 vs LSE:BPCR: 5.13

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), BioPharma Credit's stock price is $0.846. BioPharma Credit's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $0.134. Therefore, BioPharma Credit's PE Ratio for today is 6.31.


BioPharma Credit EV-to-FCF Historical Data

The historical data trend for BioPharma Credit's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPharma Credit EV-to-FCF Chart

BioPharma Credit Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial 8.40 20.24 12.81 6.15 8.18

BioPharma Credit Semi-Annual Data
Jun17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 12.81 - 6.15 8.18

Competitive Comparison of BioPharma Credit's EV-to-FCF

For the Asset Management subindustry, BioPharma Credit's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioPharma Credit's EV-to-FCF Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, BioPharma Credit's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where BioPharma Credit's EV-to-FCF falls into.



BioPharma Credit EV-to-FCF Calculation

BioPharma Credit's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=945.156/184.277
=5.13

BioPharma Credit's current Enterprise Value is $945.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioPharma Credit's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 was $184.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioPharma Credit  (LSE:BPCR) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

BioPharma Credit's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.846/0.134
=6.31

BioPharma Credit's share price for today is $0.846.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioPharma Credit's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $0.134.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


BioPharma Credit EV-to-FCF Related Terms

Thank you for viewing the detailed overview of BioPharma Credit's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioPharma Credit (LSE:BPCR) Business Description

Traded in Other Exchanges
N/A
Address
65 Gresham Street, 6th Floor, London, GBR, EC2V 7NQ
BioPharma Credit PLC is an investment company. The investment objective of the company is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The only reporting segment of the company is the investment in debt assets secured by royalties or other cash flows derived from the sale of approved life sciences products. The company generates revenue in the form of interest income, income from subsidiaries, royalty revenue, make-whole and prepayment income, dividends, and paydown fees. The company earns a majority of its revenue from Investment income.

BioPharma Credit (LSE:BPCR) Headlines

No Headlines